School of Medicine


Showing 21-40 of 145 Results

  • Shefali Dujari, MD

    Shefali Dujari, MD

    Clinical Assistant Professor, Neurology & Neurological Sciences

    BioDr. Dujari is a board-certified neurologist and fellowship-trained neurohospitalist, specializing in the care of acute neurologic disorders. She practices at both Stanford Hospital and Stanford ValleyCare. She completed her medical training at Boston University, internal medicine preliminary year at California Pacific Medical Center, neurology residency at Stanford University, and neurohospitalist fellowship at Stanford University. She serves as the Neurology Resident & Fellow Wellness & Mentoring Committee faculty lead, the associated program director of the Stanford Neurohospitalist Fellowship, and the physician lead of the ValleyCare Neuroscience Quality Committee. She has a special interest in medical education and quality improvement.

    For more information on the Stanford Neurohospitalist Program & Fellowship, please visit: https://med.stanford.edu/neurology/divisions/neurohospitalist.html

  • Jeffrey Dunn, MD

    Jeffrey Dunn, MD

    Clinical Professor, Neurology & Neurological Sciences

    Current Research and Scholarly InterestsTranslational research in the human application of emerging immunotherapies for neurological disease, focusing on Multiple Sclerosis, CIS, transverse myelitis and Neuromyelitis Optica (NMO). Collaborative research with Stanford and extramural scientific faculty to identify biomarkers of disease activity and treatment response in humans. Clinical trials to assess efficacy of emerging treatments for MS, CIS and NMO.

  • Emmanuel During, MD

    Emmanuel During, MD

    Clinical Associate Professor, Neurology & Neurological Sciences

    Current Research and Scholarly InterestsImproving diagnostics and therapeutics in RBD, using home ambulatory devices including wearable actigraphy, dry-EEG, to power clinical trials based on objective outcomes of RBD activity.

    Controlling symptoms of RBD testing drugs rigorously.

    Predicting the course of neurodegeneration using deep phenotyping using clinical and serum biomarkers, measures of autonomic impairment, skin biopsy, microbiome

  • Rouzbeh Fateh, MD

    Rouzbeh Fateh, MD

    Clinical Assistant Professor, Neurology & Neurological Sciences

    BioDr. Fateh is a fellowship-trained neurologist, specializing in neuromuscular disorders. He is an assistant professor with the Stanford School of Medicine Department of Neurology. His background includes extensive work in neurology, mental health, and neurodevelopmental disabilities.

    His practice focuses on providing comprehensive care for complex neurological and neuromuscular diseases. His expertise includes neuropathies, myopathies, and other brain and nerve-related disorders. He is board-certified in neurology, clinical neurophysiology, and electrodiagnostic medicine.

    Dr. Fateh was involved in research related to neurodevelopmental disabilities and multiple sclerosis. His work has been published in international journals such as Swiss Medical Weekly and The World Journal of Biological Psychiatry.

    He has also given numerous presentations in different meetings including annual meeting of the American Academy of Neurology.

    Additional languages spoken: Farsi, Turkish (Azeri dialect)

  • Margaret S. Ferris, MD

    Margaret S. Ferris, MD

    Clinical Assistant Professor, Neurology & Neurological Sciences

    BioDr. Ferris is a fellowship-trained neurologist and Clinical Assistant Professor in the Department of Neurology, Division of Movement Disorders.

    She diagnoses and treats a breath of movement disorders such as Parkinson’s disease and essential tremor. She recognizes the broad effects of these conditions on daily living and aims to develop personalized, comprehensive treatment plans that optimize health and quality of life.

    Dr. Ferris research interests focus on access to interventional therapies for movement disorders. She has participated in investigations sponsored by the National Institutes of to evaluate advanced treatments for complications of Parkinson’s disease.

    She has co-authored articles in publications such as Nature, The Neurohospitalist, and BioMed Central (BMC) Genomics. She has presented her insights about innovations in the understanding, detection, and management of movement disorders at conferences including, the Society for Neuroscience Annual Meeting, Pan American Parkinson’s Disease and Movement Disorders Congress.

    She is a member of the American Academy of Neurology and the Movement Disorder Society.

  • Anna Finley Caulfield, MD

    Anna Finley Caulfield, MD

    Clinical Professor, Neurology & Neurological Sciences

    Current Research and Scholarly InterestsDr. Finley joined the Stanford Stroke Center in 2004 from Beth Israel Deaconess Medical Center in Boston. She cares for acute stroke patients and other neurologically critical ill patients in the intensive care unit. Currently, her research interests include hypothermia after cardiac arrest and comparing health care provider's predications of future neurological function in neurologically critical ill patients to their 6-month outcome.

  • Robert Fisher, MD, PhD

    Robert Fisher, MD, PhD

    The Maslah Saul, MD, Professor and Professor, by courtesy, of Neurosurgery

    Current Research and Scholarly InterestsDr. Fisher is interested in clincal, laboratory and translational aspects of epilepsy research. Prior work has included: electrical deep brain stimulation for epilepsy, studied in laboratory models and clinical trials; drug delivery to a seizure focus; mechanisms of absence epilepsy studied with in vitro slices of brain thalamus; hyperthermic seizures; diagnosis and treatment of non-epileptic seizures, the post-ictal state; driving and epilepsy; new antiepileptic drugs; surgery for epilepsy.

  • Andrea Fuentes

    Andrea Fuentes

    Clinical Assistant Professor, Neurology & Neurological Sciences

    BioDr. Fuentes is a board-certified neurologist with the Movement Disorders Center at Stanford Health Care. She is also a clinical assistant professor in the Department of Neurology and Neurological Sciences. Dr. Fuentes completed a movement disorders fellowship at the University of California, San Francisco.

    She provides comprehensive care for patients with different types of movement disorders, including Parkinson’s disease (PD), atypical parkinsonian disorders, essential tremor, ataxia, dystonia, and chorea. As part of her clinical practice, she performs deep brain stimulation (DBS) evaluation and programming and botulinum toxin injections.

    Her research efforts include several clinical trials assessing treatments for movement disorders. She has been a sub-investigator on multiple trials evaluating drug candidates for the treatment of PD and ataxia. She has presented her work at national and international meetings, including those for the International Parkinson and Movement Disorder Society and the American College of Physicians.

    Dr. Fuentes is a member of the American Academy of Neurology and the International Parkinson and Movement Disorder Society.

  • Kristin Galetta, MD

    Kristin Galetta, MD

    Clinical Assistant Professor, Neurology & Neurological Sciences

    BioDr. Galetta is a board-certified neurologist within the Neurohospitalist and Neuroimmunology divisions. She completed a multiple sclerosis (MS) fellowship at Brigham and Women’s Hospital.

    She has extensive experience diagnosing and treating patients with autoimmune neurologic conditions including multiple sclerosis, optic neuritis, autoimmune encephalitis and transverse myelitis. Her research interests are focused on understanding best treatment strategies for patients with multiple sclerosis and more rare autoimmune neurologic conditions. She also has an interest in medical education improvement.

    She has published in numerous peer-reviewed journals, including the Journal of Neurological Sciences and Multiple Sclerosis and Related Disorders. She is a peer reviewer for multiple prestigious journals, including Neurology and Frontiers in Neurology.

  • Paul George, MD, PhD

    Paul George, MD, PhD

    Assistant Professor of Neurology (Adult Neurology) and, by courtesy, of Neurosurgery

    Current Research and Scholarly InterestsCONDUCTIVE POLYMER SCAFFOLDS FOR STEM CELL-ENHANCED STROKE RECOVERY:
    We focus on developing conductive polymers for stem cell applications. We have created a microfabricated, polymeric system that can continuously interact with its biological environment. This interactive polymer platform allows modifications of the recovery environment to determine essential repair mechanisms. Recent work studies the effect of electrical stimulation on neural stem cells seeded on the conductive scaffold and the pathways by which it enhances stroke recovery Further understanding the combined effect of electrical stimulation and stem cells in augmenting neural repair for clinical translational is a major focus of this research going forward.

    BIOPOLYMER SYSTEMS FOR NEURAL RECOVERY AND STEM CELL MODULATION:
    The George lab develops biomaterials to improve neural recovery in the peripheral and central nervous systems. By controlled release of drugs and molecules through biomaterials we can study the temporal effect of these neurotrophic factors on neural recovery and engineer drug delivery systems to enhance regenerative effects. By identifying the critical mechanisms for stroke and neural recovery, we are able to develop polymeric technologies for clinical translation in nerve regeneration and stroke recovery. Recent work utilizing these novel conductive polymers to differentiate stem cells for therapeutic and drug discovery applications.

    APPLYING ENGINEERING TECHNIQUES TO DETERMINE BIOMARKERS FOR STROKE DIAGNOSTICS:
    The ability to create diagnostic assays and techniques enables us to understand biological systems more completely and improve clinical management. Previous work utilized mass spectroscopy proteomics to find a simple serum biomarker for TIAs (a warning sign of stroke). Our study discovered a novel candidate marker, platelet basic protein. Current studies are underway to identify further candidate biomarkers using transcriptome analysis. More accurate diagnosis will allow for aggressive therapies to prevent subsequent strokes.

  • Carl Gold

    Carl Gold

    Clinical Associate Professor, Neurology & Neurological Sciences
    Clinical Associate Professor (By courtesy), Neurosurgery

    BioDr. Gold is a board-certified neurologist who is fellowship-trained in the diagnosis and treatment of neurological disorders in hospitalized patients. He cares for a broad range of patients, including individuals with seizures, central nervous system infections, autoimmune diseases, headaches, neuromuscular conditions, and neurological complications of cancer. Dr. Gold's primary research interest focuses on enhancing the communication skills of neurology residents, and he serves as the Director of the Stanford Neurology Residency Communication Coaching Program. He is also the Fellowship Director of the Stanford Neurohospitalist Fellowship.

    Dr. Gold serves as Vice Chair of Quality, Safety, & Experience for the Department of Neurology & Neurological Sciences. In this role, he coordinates projects aimed at improving care for patients with neurological conditions across the health system.

    For more information on the Stanford Neurohospitalist Program & Fellowship, please visit: https://med.stanford.edu/neurology/divisions/neurohospitalist.html

    Learn more about the Stanford Neurology Communication Coaching Program by visiting: http://med.stanford.edu/neurology/education/resident-coaching.html

    Additional information on Stanford Neurology's efforts in Quality, Safety, & Value can be found here: http://med.stanford.edu/neurology/quality.html

  • Olga Fedin Goldberg

    Olga Fedin Goldberg

    Clinical Associate Professor, Neurology & Neurological Sciences

    BioDr. Goldberg is board-certified in Neurology by the American Board of Psychiatry and Neurology. She provides comprehensive neurologic care to patients with a broad range of neurologic conditions, including those who have multiple neurologic conditions. She is interested in medical education for neurology residents and for referring primary care providers and serves as Director of Neurology Resident Continuity Clinic. Additionally, she completed the Stanford CELT (Clinical Education Leadership Training) Program for developing skills in quality improvement. She has led or played a key role in multiple quality improvement projects in the Department of Neurology, including those focused on increasing patient understanding of their neurologic medications upon hospital discharge, improvement of outcomes for headache patients seen in primary care, and in optimizing clinic processes involved in collection of cerebrospinal fluid.

  • Neelam Goyal, MD

    Neelam Goyal, MD

    Clinical Associate Professor, Neurology & Neurological Sciences

    Current Research and Scholarly InterestsDr. Goyal's research interests involve monitoring and managing the short and long-term toxicity of immunosuppressive agents used in the treatment of immune-mediated neuromuscular disorders. She is actively involved in a grant-supported project investigating steroid toxicity in patients with myasthenia gravis.

    She also serves as the Wellbeing Co-Director for the Neurology Department, working on a grant-supported project aimed at mitigating the adverse impact of work on personal relationships.

  • Maxwell Greene, MD

    Maxwell Greene, MD

    Clinical Assistant Professor, Neurology & Neurological Sciences

    BioDr. Greene is a board-certified, fellowship-trained neurologist. He is also a Clinical Assistant Professor of Neurology at Stanford University School of Medicine.

    Dr. Greene provides clinical care for adult patients with disorders of the muscles and peripheral nerves that cause weakness and numbness. He specializes in diagnosing and treating neuromuscular diseases that include amyotrophic lateral sclerosis (ALS), all types of muscular dystrophy, chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, and Charcot-Marie-Tooth (CMT). For CIDP and CMT, Stanford is one of the few centers of excellence in the country.

    A significant part of Dr. Greene’s practice involves investigational work, where he seeks to determine the cause of a patient’s symptoms. In addition to performing the full range of diagnostic tests including interpreting biopsy procedures, he has special qualifications in electrodiagnosis and the use of electromyography and nerve conduction studies.

    Treatments offered by Dr. Greene cover the complete spectrum of options, with an emphasis on immune therapies for certain conditions. For CIDP and myasthenia gravis, he administers immune globulin, steroids, plasmapheresis, and rituximab. To help manage symptoms of CMT and support areas of the body weakened by this disease, he can recommend physical therapy, occupational therapy, and foot, ankle, and knee orthotics.

    For the treatment of ALS and muscular dystrophy, Dr. Greene leads a multidisciplinary team offering physical and occupational therapy, pulmonary expertise, speech and swallow expertise, nutrition counseling, social services, and specialized nursing, and works together with genetic counseling. All team members collaborate closely to ensure patients receive the care and comfort needed to meet their emotional as well as physical needs.

    As part of his commitment to advancing patients’ treatment options, Dr. Greene conducts clinical research. Among his current interests are
    innovative new therapies for ALS and other nerve and muscular disorders. This is an exciting time in the field of neuromuscular medicine, with real potential for treatment breakthroughs for the first time in decades. Exploring these new directions enables Dr. Greene to offer Stanford patients access to options that may not be available anywhere else.

    To highlight new advances for his peers, Dr. Greene has made national and regional presentations at conferences including the American Academy of Neurology meeting. Topics include the results of a study supported in part by the National Institutes of Health: paraneoplastic antibodies as markers of Hodgkin’s disease. JAMA Neurology published Dr. Greene’s article on this research.

    Dr. Greene’s achievements have earned recognition from the American Academy of Neurology and other organizations. He is also the recipient of a travel award from the American Neurological Association and a grant from the NIH National Institute of Neurological Disorders and Stroke.

    A member of the American Academy of Neurology, Dr. Greene is also an active member of the Western ALS Consortium and Northeastern ALS Consortium.

  • Michael Greicius, MD, MPH

    Michael Greicius, MD, MPH

    Iqbal Farrukh and Asad Jamal Professor and Professor, by courtesy, of Psychiatry and Behavioral Sciences (Administrative and Academic Special Programs)

    Current Research and Scholarly InterestsAs the Medical Director of the Stanford Center for Memory Disorders and Principal Investigator of the Stanford Extreme Phenotypes in Alzheimer's Disease (StEP AD) Cohort, Dr. Greicius' research focuses on elucidating the neurobiologic underpinnings of AD. His lab combines cutting edge brain imaging, "deep" phenotyping, and whole-genome sequencing of human subjects to identify novel pathways involved in AD pathogenesis. The goal of his work is to develop effective treatment for AD patients.

  • Jin S. Hahn, MD

    Jin S. Hahn, MD

    Professor of Neurology at the Stanford University Medical Center, Emeritus

    Current Research and Scholarly Interests1. Clinical informatics and electronic health records
    2. Neonatal and fetal neurology
    3. Prenatal diagnosis neurodevelopmental anomalies
    4. Personalized Health and Wellness Records

  • May Han, MD

    May Han, MD

    Associate Professor of Neurology (Adult Neurology)

    Current Research and Scholarly InterestsMultiple sclerosis
    Neuromyelitis optica
    Autoimmune CNS disorders